- Home
- DXR vs ATYR Comparison
DXR vs ATYR Comparison
Compare DXR & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | ATYR |
|---|---|---|
| Founded | 1970 | 2005 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 83.3M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXR | ATYR |
|---|---|---|
| Price | $11.48 | $0.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | ★ $25.00 | $4.20 |
| AVG Volume (30 Days) | 10.3K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | $9,628.95 |
| Revenue Next Year | N/A | $156.94 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.10 | $0.64 |
| 52 Week High | $14.76 | $7.29 |
Technical Indicators
Market Signals| Indicator | DXR | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 43.50 |
| Support Level | $11.31 | $0.82 |
| Resistance Level | $14.02 | $0.85 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 32.82 | 7.78 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).